DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

NCT03879798 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped Due to DLTs

Conditions

Small Cell Lung Cancer

Interventions

DRUG: DS-3201b
DRUG: irinotecan

Sponsor

Memorial Sloan Kettering Cancer Center